Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus

Ropert, Catherine; Lavignon, Marc; Dubernet, Catherine; Couvreur, Patrick; Malvy, Claude

doi:10.1016/0006-291x(92)90565-3

Cited by 82 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This event induces a fusion of the liposome membrane with the endosomal membrane, and the content of the liposomes is then directly unloaded into the cell cytoplasm. A pH-sensitive liposome formulation of an AS-ON directed against the env mRNA of the Friend retrovirus was able to control the viral infection in cells more effectively than the non-pH-sensitive liposome formulation, whereas the free control and AS-ON lack antiviral activity (219). It was shown that the cell uptake of the pH-sensitive liposomes depended greatly on the virus exit process leading to the conclusion that it may result from the activation of cell pinocytosis because of the virus budding (220,221).…”

Section: Treatments Against Infectionsmentioning

confidence: 96%

Nanotechnology: Intelligent Design to Treat Complex Disease

2006

Self Cite

View full text Add to dashboard Cite

The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the "magic bullet" proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.

show abstract

Section: Treatments Against Infectionsmentioning

confidence: 96%

Nanotechnology: Intelligent Design to Treat Complex Disease

2006

Self Cite

View full text Add to dashboard Cite

show abstract

“…The transfer of the DOPE molecules to the endosomal membrane is thought to promote endosome leakage [101], although the precise mechanism remains to be elucidated [104]. Such pH-sensitive liposomes have shown efficient in vitro cytosolic delivery of model fluorescent probes [105] and oligonucleotides (ODN) [106]. However, the in vivo efficacy is more questionable, mainly due to stability concerns in the presence of serum [107].…”

Section: Surface Chargementioning

confidence: 99%

Nanocarriers’ entry into the cell: relevance to drug delivery

Hillaireau

Couvreur

2009

Cell. Mol. Life Sci.

Self Cite

1,359

1,015

View full text Add to dashboard Cite

Nanocarriers offer unique possibilities to overcome cellular barriers in order to improve the delivery of various drugs and drug candidates, including the promising therapeutic biomacromolecules (i.e., nucleic acids, proteins). There are various mechanisms of nanocarrier cell internalization that are dramatically influenced by nanoparticles' physicochemical properties. Depending on the cellular uptake and intracellular trafficking, different pharmacological applications may be considered. This review will discuss these opportunities, starting with the phagocytosis pathway, which, being increasingly well characterized and understood, has allowed several successes in the treatment of certain cancers and infectious diseases. On the other hand, the non-phagocytic pathways encompass various complicated mechanisms, such as clathrin-mediated endocytosis, caveolae-mediated endocytosis and macropinocytosis, which are more challenging to control for pharmaceutical drug delivery applications. Nevertheless, various strategies are being actively investigated in order to tailor nanocarriers able to deliver anticancer agents, nucleic acids, proteins and peptides for therapeutic applications by these non-phagocytic routes.

show abstract

“…84 Two decades ago, Ropert et al encapsulated an antisense complementary to the region of the initiation codon AUG of the Env gene mRNA of Friend retrovirus which was an inhibitor of the translation of Env protein in vitro. 85 They used DOPE, oleic acid and cholesterol in ratio 10:5:2 for pH-sensitive liposomes and DOPC, oleic acid and cholesterol in ratio 10:5:2 for non pH-sensitive liposomes. The results showed higher activity of AUG antisense encapsulated in pH-sensitive liposomes and the ability to avoid lysosomal degradation of oligomers.…”

Section: Ph-responsive Liposomesmentioning

confidence: 99%